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INTRODUCTION
Bullus pemphigoid (BP) represents the most frequent 
autoimmune blistering disease in Europe. It typically 
affects the elderly and is associated with a significant 
morbidity and mortality. The disorder is characterized 
by autoantibodies directed against BP180 (collagen 
type XVII, BPAg2) and less often BP230 (BPAg1). 
Recent studies have revealed that eventual blister 
formation is the result of multiple complex interac-
tions involving autoantibody binding and comple-
ment activation leading to activation of cells such 
as neutrophils, eosinophils, and mast cells. Disease 
presentation may be limited to a localized form or 
may present with a widespread, generalized blistering 
eruption. As a result, treatment of BP depends greatly 
on the extent of disease as well as patient comorbidi-
ties. First-line treatments are typically general immu-
nosuppressives1-7. More extensive disease is usually 
treated with oral prednisone, which is the mainstay of 
therapy. Although the optimal dosing and formulation 
of systemic corticosteroid therapy remains unclear, 
the complications of such therapy (including osteopo-
rosis, diabetes, hypertension, cataracts, glaucoma, and 
systemic infection) are well documented and may be 
severe, particularly in the elderly with co-morbidities. 
Τherefore, it is important to minimize the total dose 
and duration of therapy with oral glucocorticoids. 8-9 
The addition of steroid-sparing agents may facilitate 
tapering of systemic corticosteroids and help to mini-
mize corticosteroid-associated adverse events.
CASE REPORT
A 73-year-old man was referred to our clinic with a 
generalized pruritic bullus eruption. The eruption, 
that had first presented 2 months ago, was multiforme 
and consisted of tense, bullae, 3-5 cm in diameter, on 
erythematous skin as well as of eroded and crusted 
lesions localized on the trunk, abdomen, chest, upper 
and lower extremities, thighs and scalp. 
According to his medical history the patient was 
also suffering from glaucoma, cataract, diabetes mel-
litus and duodenal ulcer.
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Diagnosis of BP was based on clinical and histo-
pathologic criteria as well as on findings from direct 
and indirect immunofluorescence.
Histological examination revealed subepidermal 
blister with a dermal inflammatory infiltrate com-
posed predominantly of eosinophils and neutrophils. 
Direct immunofluorescence (DIF) examination 
characteristically showed continuous linear deposits 
of IgG along the epidermal basement membrane The 
indirect immunofluorescence (IIF) study revealed cir-
culating IgG autoantibodies  typically binding to the 
epidermal side of salt-split normal human skin.
Clinical and laboratory investigation was unre-
markable and revealed no further abnormalities.  
Due to his medical history and in order to mini-
mize the possibility of adverse events as well as to in-
crease patients tolerability methylprednisolone pulse 
therapy was initiated.  
Treatment cycle consisted of administration of 
methylprednisolone intravenously (15 mg/kg in 16 
mL of bacteriostatic water over a period of 30-60 min/ 
day)- for two consecutive days, followed by a five 
days rest period. Clinical examination, revealed erup-
tion of a few new lesions localized on the trunk.
Sustained remission without eruption of new le-
sions was achieved after two treatment cycles. During 
the whole treatment period laboratory investigations 
was normal. 
Complete remission and re-epithelialization with 
healing of all lesions was observed after four cycles 
of I.M.P.T.
Pulse intravenous methylprednisolone therapy 
was discontinued and treatment with cyclophospha-
mide, at the dose of 50 mg twice daily was initiated.
At a three weeks follow-up, his general condition 
was excellent with a total resolution of the pemphi-
goid lesions. Re-epithelialization and healing of all 
lesions was achieved, while no new lesions appeared.
Today, four months after discontinuation of intra-
venous methylprednisolone pulse therapy (I.M.P.T.) 
the patient remains free of new lesions, receiving only 
per os cyclophosphamide at a dosage of 50mg twice 
daily.
DISCUSSION
Bullous pemphigoid (BP), is the most common au-
toimmune blistering disease in Western countries. 
The mortality rate in patients with BP is high, rang-
ing from 10% to 40% after 1 year, possibly related 
to the advanced age of most patients, many of whom 
have multiple co-morbidities and⁄or an already altered 
general condition. The high doses of systemic steroids 
often used to treat this condition is also another factor 
contributing to the forementioned observed rate. Sys-
temic corticosteroids are widely used in daily clinical 
practice, and their efficacy has been confirmed in un-
controlled and controlled studies. However, their use 
can be associated with significant side effects.
For patients with extensive disease, oral pred-
nisone, at the dosage of 0.5 to 1 mg/kg/d, usually 
achieve control of the disease within 3 weeks. This 
dose is then progressively tapered over a period of 6 
to 9 months10-13.
To minimize the iatrogenic effects of systemic 
corticosteroids, alternative therapies have been in-
troduced such as immunosuppressive drugs (aza-
thioprine, cyclophosphamide, methotrexate, myco-
phenolate mofetil), gold, tetracyclines, dapsone, and 
intravenous immunoglobulins. The use of immuno-
suppressive drugs, such as azathioprinemycophenolate mofetil, 
methotrexate, and, less frequently, chlorambucil and 
cyclophosphamide, is a matter of debate. Some clini-
cians introduce them only when corticosteroids alone 
fail to control the disease or if the latter are contra-
indicated. The choice of an immunosuppressive drug 
depends on the profile of its side effects, the patient’s 
overall condition, the experience of the physician with 
the pharmaceutical agent, and finally, cost issues. Al-
though mycophenolate mofetil, for example, is likely 
to have less hepatic side effects compared with aza-
thioprine, the latter is much cheaper and may show a 
more rapid onset of action with a better corticosteroid-
sparing effect. Dapsone, as well as the association of 
nicotinamide and minocycline or tetracycline, have 
also been tried alone or as adjuvant therapy with some 
success  and may be helpful in mild disease. The ex-
perience with biological agents in BP, such as ritux-
imab, is still anecdotal, but in certain situations, they 
likely represent the last therapeutic option available 
to try14-21.
Pulse therapy with steroids is reported to reduce 
the morbitity and mortality in pemphigus vulgaris. 
This treatment regimen was first described by Paris-
cha et al22. Pulse therapy, the big shot, refers to the dis-
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continuous intravenous infusion of very high doses of 
corticosteroids over a short time. Doses of each pulse 
are not standardized but are usually 500-1000 mg 
methylprednisolone or 100-200 mg dexamethasone. 
The number of pulses required to induce remission 
varies between patients. The aim of pulse therapy is to 
achieve a faster response and stronger efficacy and to 
decrease the need for long-term use of systemic corti-
costeroids.  The reduction in daily steroid requirement 
following pulse therapy is a major advantage of this 
therapy. Although large doses of steroid are used in 
the pulse regime, it is clear that the route of adminis-
tration of steroids is important in determining steroid 
related adverse effects, with intermittent intravenous 
methylprednisolone pulse therapy having a distinct 
pharmacological profile compared with moderate, 
daily oral corticosteroids23. There are only a few re-
ports on the efficacy and safety of pulse therapy in BP 
treatment24.
Based on these reports there seems to be no differ-
ence in efficacy in newly diagnosed and previously 
treated cases. It appears to be a good alternative to the 
standard continuous corticosteroid treatment.  
In conclusion, pulse therapy with methylpred-
nisolone for BP treatment is a cost-effective option 
although appropriate patient selection and rigid moni-
toring is essential in view of its toxicity profile. The 
optimum dosing regimen remains to be determined in 
a well conducted randomized controlled clinical trial, 
preferably in comparison to the mainstay treatment 
schema and with short and medium term safety out-
comes included in the protocol analysis.
ΠΕΡΙΛΗΨΗ: Παρουσιάζεται περίπτωση εκτεταμένου πομφολυγώδους πεμφιγοειδούς σε άντρα ηλικίας 73 ετών, που λόγω 
του ιατρικού του ιστορικού (καταρράκτης, γλαύκωμα, σακχαρώδης διαβήτης και έλκος δωδεκαδακτύλου), δεν μπορούσε να 
λάβει από του στόματος αγωγή με υψηλή δόσης στεροειδών. Η νόσος αντιμετωπίσθηκε επιτυχώς με συνδυασμό ενδοφλέ-
βιας έγχυσης κατά ώσεις μεθυλπρεδνιζολόνης και από του στόματος χορήγηση κυκλοφωσφαμίδης. Με την ευκαιρία του 
περιστατικού αναφέρονται συνοπτικά οι θεραπευτικές επιλογές για την αντιμετώπιση του   πομφολυγώδους πεμφιγοειδούς 
και δίνεται ιδιαίτερη έμφαση στη μέθοδο έγχυσης μεθυλπρεδνιζολόνης κατά ώσεις.
Λέξεις Κλειδία: Πομφολυγώδες πεμφιγοειδές, Θεραπεία, Μεθυλπρεδνιζολόνη, Κυκλοφωσφαμίδη.
Επιτυχής αντιμετώπιση πομφολυγώδους πεμφιγοειδούς με συνδυασμό ενδοφλέβιας 
έγχυσης κατά ώσεις μεθυλπρεδνιζολόνης και από του στόματος χορήγηση  
κυκλοφωσφαμίδης. Παρουσίαση περιστατικού.
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